NCT04814355View on ClinicalTrials.gov

The Effect of Celecoxib on Neuroinflammation in MDD

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Major Depressive DisorderNeuroinflammation
Interventions
DRUG

Celecoxib 400 mg

Patients will receive 400 mg/day of celecoxib for 8 weeks.

Trial Locations (1)

11794-8101

Psychiatry Department at Stony Brook University, Stony Brook

Sponsors
All Listed Sponsors
collaborator

Brain & Behavior Research Foundation

OTHER

lead

Stony Brook University

OTHER